Ottenheijm Coen A C, Witt Christian C, Stienen Ger J, Labeit Siegfried, Beggs Alan H, Granzier Henk
Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85724, USA.
Hum Mol Genet. 2009 Jul 1;18(13):2359-69. doi: 10.1093/hmg/ddp168. Epub 2009 Apr 4.
Nemaline myopathy (NM) is the most common non-dystrophic congenital myopathy. Clinically the most important feature of NM is muscle weakness; however, the mechanisms underlying this weakness are poorly understood. Here, we studied the muscular phenotype of NM patients with a well-defined nebulin mutation (NM-NEB), using a multidisciplinary approach to study thin filament length regulation and muscle contractile performance. SDS-PAGE and western blotting revealed greatly reduced nebulin levels in skeletal muscle of NM-NEB patients, with the most prominent reduction at nebulin's N-terminal end. Muscle mechanical studies indicated approximately 60% reduced force generating capacity of NM-NEB muscle and a leftward-shift of the force-sarcomere length relation in NM-NEB muscle fibers. This indicates that the mechanism for the force reduction is likely to include shorter and non-uniform thin filament lengths in NM-NEB muscle compared with control muscle. Immunofluorescence confocal microscopy and electron microscopy studies indicated that average thin filament length is reduced from approximately 1.3 microm in control muscle to approximately 0.75 microm in NM-NEB muscle. Thus, the present study is the first to show a distinct genotype-functional phenotype correlation in patients with NM due to a nebulin mutation, and provides evidence for the notion that dysregulated thin filament length contributes to muscle weakness in NM patients with nebulin mutations. Furthermore, a striking similarity between the contractile and structural phenotypes of nebulin-deficient mouse muscle and human NM-NEB muscle was observed, indicating that the nebulin knockout model is well suited for elucidating the functional basis of muscle weakness in NM and for the development of treatment strategies.
杆状体肌病(NM)是最常见的非营养不良性先天性肌病。临床上,NM最重要的特征是肌肉无力;然而,这种无力背后的机制却知之甚少。在此,我们采用多学科方法研究细丝长度调节和肌肉收缩性能,对具有明确的伴肌动蛋白突变的NM患者(NM-NEB)的肌肉表型进行了研究。SDS-PAGE和蛋白质免疫印迹法显示,NM-NEB患者骨骼肌中的伴肌动蛋白水平大幅降低,在伴肌动蛋白的N端减少最为显著。肌肉力学研究表明,NM-NEB肌肉产生力的能力降低了约60%,且NM-NEB肌纤维中的力-肌节长度关系向左偏移。这表明,与对照肌肉相比,NM-NEB肌肉中力降低的机制可能包括细丝长度较短且不均匀。免疫荧光共聚焦显微镜和电子显微镜研究表明,平均细丝长度从对照肌肉中的约1.3微米减少到NM-NEB肌肉中的约0.75微米。因此,本研究首次展示了由于伴肌动蛋白突变导致的NM患者中独特的基因型-功能表型相关性,并为细丝长度失调导致伴肌动蛋白突变的NM患者肌肉无力这一观点提供了证据。此外,还观察到伴肌动蛋白缺陷小鼠肌肉和人类NM-NEB肌肉的收缩和结构表型之间存在惊人的相似性,这表明伴肌动蛋白基因敲除模型非常适合阐明NM中肌肉无力的功能基础以及开发治疗策略。